Citations

Clear

2391 citation(s) found for "Xu, Lin".

Women’s Experience With Screening Mammography During the COVID-19 Pandemic: A Multi-Institutional Prospective Survey Study
Carnahan, Molly B. , Parra, Laura , Hippe, Daniel S. , Lorans, Roxanne, Perry, Hannah , Moey, Tammy Hui Lin , Bagadiya, Neeti, Lee, Janie M. , Sharpe, Richard E. , Hippe, Daniel S , Moey, Tammy Hui Lin , Harrison, Molly , Oluyemi, Eniola T.

Mayo Clinic

Journal of Breast Imaging | May 13, 2022 | Volume: 4 | Issue: 3 | Pages: 253-262

10.1093/jbi/wbac022 | PMID 38416975 Get It

Abstract Objective Evaluate women’s anxiety and experience undergoing screening mammography during the COVID-19 pandemic. Methods An IRB-approved anonymous survey was administered to women receiving screening mammography across six sites in the U.S. and Singapore from October 7, 2020, to March 11, 2021. Using a 1–5 Likert scale, women rated their pre- and post-visit anxiety regarding having their mammogram during the COVID-19 pandemic, importance of observed COVID-19 precautions, and personal risk factors for breast cancer and severe COVID-19 illness. Post-visit change in anxiety was evaluated. Multivariable logistic regression was used to test associations of pre-visit anxiety with breast cancer and COVID-19 risk factors. Results In total, 1086 women completed the survey. Of these, 59% (630/1061) had >1 breast cancer risk factor; 27% (282/1060) had >1 COVID-19 risk factors. Forty-two percent (445/1065) experienced pre-visit anxiety. Pre-visit anxiety was independently associated with risk factors for severe COVID-19 (OR for >2 vs 0 risk factors: 2.04, 95% confidence interval [CI]: 1.11–3.76) and breast cancer (OR for >2 vs 0 risk factors: 1.71, 95% CI: 1.17–2.50), after adjusting for age and site. Twenty-six percent (272/1065) of women reported post-visit anxiety, an absolute 16% decrease from pre-visit anxiety (95% CI: 14%–19%, P < 0.001). Provider masking (941/1075, 88%) and physical distancing (861/1085, 79%) were rated as the most important precautions. Conclusion Pre-visit anxiety was associated with COVID-19 or breast cancer risk factors and declined significantly after screening mammography. Provider masking and physical distancing were rated the most important precautions implemented by imaging clinics.
Abstract 47: Tapering And Discontinuation Of Background Therapies During The Transition To Rilonacept Monotherapy In Rhapsody, A Phase 3 Clinical Trial Of Rilonacept In Patients With Recurrent Pericarditis
Wheeler, Alistair, Abbate, Antonio , Fang, Fang , LeWinter, Martin M. , Lin, David , Chatfield, Jay B, Paolini, John F. , Brucato, Antonio , Wheeler, Alistair, Luis, Sushil Allen , Cremer, Paul , Insalaco, Antonella , Lewis, Basil S. , Nicholls, Stephen J. , Klein, Allan L. , Imazio, Massimo

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 12, 2022 | Volume: 15 | Issue: Suppl_1 | Pages: No page available

10.1161/circoutcomes.15.suppl_1.47 Get It

Background: Post-episode tapering of Standard of Care (SoC) medication in patients with recurrent pericarditis (RP) varies considerably. Gradual tapering of corticosteroids (CS) is recommended in ESC guidelines (decreasing by 1-2.5 mg/day every 2-6 weeks over 1-2 years) to prevent recurrence. We describe successful faster tapering of SoC treatment onto rilonacept monotherapy during RHAPSODY, a Phase 3, placebo-controlled, randomized-withdrawal (RW) trial in RP. Methods: Patients with acute symptomatic RP despite stable doses of NSAIDs, colchicine, and/or CS in any combination enrolled in a 12-week run-in period in which weekly rilonacept was initiated. After 1-week of stabilization, tapering of CS began at a rate dependent on baseline dose, to be completed by Week 10 for randomization at Week 12 when clinical response was confirmed by reduced pain and normalized CRP levels. Colchicine tapering/discontinuation was initiated no earlier than Week 4. This analysis evaluates time to rilonacept monotherapy in subgroups receiving different combinations of background therapies. Results: 79 of 86 patients were receiving pharmacotherapy at run-in baseline. Median (95% CI) time to monotherapy (n=79) was 7.9 (7.0-8.1) weeks. Of the patients receiving CS at baseline (41/86 [48%]), 39 (95%) tapered to rilonacept monotherapy, and median time to monotherapy was 7.9 (7.1-8.1) weeks. Of the patients receiving colchicine at baseline (65/86 [76%]), 61 (94%) patients achieved rilonacept monotherapy, and median time to monotherapy was 8.0 (7.1-8.3) weeks. Patients receiving only one SoC therapy achieved rilonacept monotherapy faster (6.1 [0.4-8.1] weeks) than those receiving 2 (8.0 [6.7-9.9] weeks) or 3 (7.7 [7.0-8.3] weeks) therapies. All patients who did not achieve monotherapy had withdrawn from the study for reasons unrelated to pericarditis. Conclusion: All patients randomized in the RHAPSODY trial discontinued SoC and transitioned to rilonacept monotherapy (median time 7.9 weeks) without a recurrent pericarditis episode during run-in. With rilonacept, time to successful discontinuation of SoC, including high dose CS, was substantially more rapid than current treatment practices. RHAPSODY data helped support FDA approval of the first therapy for RP.
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Pacheco, Jose M., Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 11, 2022 | Volume: 20 | Issue: 5 | Pages: 497-530

10.6004/jnccn.2022.0025 | PMID 35545176 Get It

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions
Eastham, James A., Auffenberg, Gregory B. , Barocas, Daniel A. , Crispino, Tony, Davis, John W. , Eggener, Scott E. , Horwitz, Eric M. , Kirkby, Erin, Lin, Daniel W. , McBride, Sean M. , Rodrigues, George , Wong, William W. , Boorjian, Stephen A. , Chou, Roger , Kane, Christopher J. , Morgans, Alicia K. , Pierorazio, Phillip

Mayo Clinic

Journal of Urology | May 10, 2022 | Volume: 208 | Issue: 1 | Pages: 26-33

10.1097/ju.0000000000002759 | PMID 35536141 Get It

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up
Eastham, James A., Auffenberg, Gregory B. , Barocas, Daniel A. , Crispino, Tony, Davis, John W. , Eggener, Scott E. , Horwitz, Eric M. , Kirkby, Erin, Lin, Daniel W. , McBride, Sean M. , Rodrigues, George , Wong, William W. , Boorjian, Stephen A. , Chou, Roger , Kane, Christopher J. , Morgans, Alicia K. , Pierorazio, Phillip

Mayo Clinic

Journal of Urology | May 10, 2022 | Volume: 208 | Issue: 1 | Pages: 19-25

10.1097/ju.0000000000002758 | PMID 35536148 Get It

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
Eastham, James A., Auffenberg, Gregory B. , Barocas, Daniel A. , Crispino, Tony, Davis, John W. , Eggener, Scott E. , Horwitz, Eric M. , Kirkby, Erin, Lin, Daniel W. , McBride, Sean M. , Rodrigues, George , Wong, William W. , Boorjian, Stephen A. , Chou, Roger , Kane, Christopher J. , Morgans, Alicia K. , Pierorazio, Phillip

Mayo Clinic

Journal of Urology | May 10, 2022 | Volume: 208 | Issue: 1 | Pages: 10-18

10.1097/ju.0000000000002757 | PMID 35536144 Get It

Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
Aizer, Ayal A. , Lamba, Nayan , Ahluwalia, Manmeet S. , Aldape, Kenneth , Boire, Adrienne , Brown, Paul D. , Camidge, D. Ross , Chiang, Veronica , Davies, Michael A. , Hu, Leland , Huang, Raymond Y. , Kumthekar, Priya , Lam, Keng , Lee, Eudocia Q. , Parsons, Michael , Reardon, David A. , Sheehan, Jason P. , Tawbi, Hussein A. , Weller, Michael , Wen, Patrick Y. , Kaufmann, Timothy, Kumthekar, Priya , Parsons, Michael W , Soffietti, Riccardo , Tawbi, Hussein , Weller, Michael , Ahluwalia, Manmeet S , Huang, Raymond , Brastianos, Priscilla K. , Kaufmann, Timothy J. , Lin, Nancy U. , Mehta, Minesh P. , Soffietti, Riccardo , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | May 3, 2022 | Volume: 24 | Issue: 10 | Pages: 1613-1646

10.1093/neuonc/noac118 | PMID 35762249 Get It

Abstract Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is known about brain metastases than cancer-related entities of similar incidence. Advances in oncologic care have heightened the importance of intracranial management. Here, in this consensus review supported by the Society for Neuro-Oncology (SNO), we review the landscape of brain metastases with particular attention to management approaches and ongoing efforts with potential to shape future paradigms of care. Each coauthor carried an area of expertise within the field of brain metastases and initially composed, edited, or reviewed their specific subsection of interest. After each subsection was accordingly written, multiple drafts of the manuscript were circulated to the entire list of authors for group discussion and feedback. The hope is that the these consensus guidelines will accelerate progress in the understanding and management of patients with brain metastases, and highlight key areas in need of further exploration that will lead to dedicated trials and other research investigations designed to advance the field.
Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk
Tian, Yu , Kim, Andre E. , Harrison, Tabitha A. , Carreras‐Torres, Robert , Díez‐Obrero, Virginia , Drew, David A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Obón‐Santacana, Mireia , Ose, Jennifer , Duijnhoven, Fränzel J.B. van , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Brenner, Hermann , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Harlid, Sophia , Hoffmeister, Michael , Joshi, Amit D. , Li, Li , Nan, Hongmei , Nassir, Rami , Prentice, Ross L. , Rennert, Gad , Slattery, Martha L. , Thibodeau, Stephen N. , Guelpen, Bethany Van , Visvanathan, Kala , White, Emily , Woods, Michael O. , Wu, Anna H. , Casey, Graham , Kundaje, Anshul , Pardamean, Bens , Thomas, Duncan C. , Tsilidis, Konstantinos K. , Peters, Ulrike , Gauderman, W. James, Chang‐Claude, Jenny , Carreras-Torres, Robert , Drew, David A , Huyghe, Jeroen R , Jordahl, Kristina M , Murphy, Neil , Ulrich, Cornelia M , Ose, Jennifer , Peoples, Anita R , Ruiz-Narvaez, Edward , van Duijnhoven, Fränzel J B , Arndt, Volker , Bishop, D Timothy , Brenner, Hermann , Buchanan, Daniel D , Figueiredo, Jane C , Gruber, Stephen B , Harlid, Sophia , Hoffmeister, Michael , Jenkins, Mark A , Larsson, Susanna C , Marchand, Loïc Le , Li, Li , Giles, Graham G , Milne, Roger L , Nassir, Rami , Ogino, Shuji , Budiarto, Arif , Platz, Elizabeth A. , Potter, John D , Sakoda, Lori C , Schoen, Robert E , Slattery, Martha L , Van Guelpen, Bethany , Visvanathan, Kala , Wolk, Alicja , Wu, Anna H. , Kundaje, Anshul , Moreno, Victor , Pardamean, Bens , Thomas, Duncan C , Tsilidis, Konstantinos K , Chang-Claude, Jenny , Rennert, Gad , Harrison, Tabitha A , Tian, Yu , Nan, Hongmei , Obón-Santacana, Mireia , Diez-Obrero, Virginia , Bien, Stephanie A. , Lin, Yi , Qu, Conghui , Dimou, Niki , Hidaka, Akihisa , Morrison, John L. , Murphy, Neil , Ulrich, Cornelia M. , Shcherbina, Anna , Stern, Mariana Carla , Su, Yu-Ru , Arndt, Volker , Buchanan, Daniel D. , Chan, Andrew T. , Jenkins, Mark A. , Keku, Temitope O , Larsson, Susanna C. , Marchand, Loı̈c Le , Giles, Graham G. , Milne, Roger L. , Potter, John D. , Sakoda, Lori C. , Schoen, Robert E. , Wolk, Alicja , Campbell, Peter T. , Conti, David V. , Gunter, Marc J. , Lewinger, Juan Pablo , Moreno, Vı́ctor , Newcomb, Polly A. , Hsu, Li

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2022 | Volume: 114 | Issue: 8 | Pages: 1135-1148

10.1093/jnci/djac094 | PMID 35512400 Get It

Abstract Background The use of menopausal hormone therapy (MHT) may interact with genetic variants to influence colorectal cancer (CRC) risk. Methods We conducted a genome-wide, gene-environment interaction between single nucleotide polymorphisms and the use of any MHT, estrogen only, and combined estrogen-progestogen therapy with CRC risk, among 28 486 postmenopausal women (11 519 CRC patients and 16 967 participants without CRC) from 38 studies, using logistic regression, 2-step method, and 2– or 3–degree-of-freedom joint test. A set-based score test was applied for rare genetic variants. Results The use of any MHT, estrogen only and estrogen-progestogen were associated with a reduced CRC risk (odds ratio [OR] = 0.71, 95% confidence interval [CI] = 0.64 to 0.78; OR = 0.65, 95% CI = 0.53 to 0.79; and OR = 0.73, 95% CI = 0.59 to 0.90, respectively). The 2-step method identified a statistically significant interaction between a GRIN2B variant rs117868593 and MHT use, whereby MHT-associated CRC risk was statistically significantly reduced in women with the GG genotype (OR = 0.68, 95% CI = 0.64 to 0.72) but not within strata of GC or CC genotypes. A statistically significant interaction between a DCBLD1 intronic variant at 6q22.1 (rs10782186) and MHT use was identified by the 2–degree-of-freedom joint test. The MHT-associated CRC risk was reduced with increasing number of rs10782186-C alleles, showing odds ratios of 0.78 (95% CI = 0.70 to 0.87) for TT, 0.68 (95% CI = 0.63 to 0.73) for TC, and 0.66 (95% CI = 0.60 to 0.74) for CC genotypes. In addition, 5 genes in rare variant analysis showed suggestive interactions with MHT (2-sided P < 1.2 × 10−4). Conclusion Genetic variants that modify the association between MHT and CRC risk were identified, offering new insights into pathways of CRC carcinogenesis and potential mechanisms involved.
Application of an F0-based genetic assay in adult zebrafish to identify modifier genes of an inherited cardiomyopathy
Wang, Mingmin , Li, Jiarong , Xu, Xiaolei , Ding, Yonghe , Wang, Mingmin , Bu, Haisong, Lin, Xueying , Bu, Haisong

Mayo Clinic

Disease Models & Mechanisms | April 28, 2022 | Volume: 16 | Issue: 5 | Pages: No page available

10.1242/dmm.049427 | PMID 35481478 Get It

ABSTRACT Modifier genes contribute significantly to our understanding of pathophysiology in human diseases; however, effective approaches to identify modifier genes are still lacking. Here, we aim to develop a rapid F0-based genetic assay in adult zebrafish using the bag3 gene knockout (bag3e2/e2) cardiomyopathy model as a paradigm. First, by utilizing a classic genetic breeding approach, we identified dnajb6b as a deleterious modifier gene for bag3 cardiomyopathy. Next, we established an F0-based genetic assay in adult zebrafish through injection of predicted microhomology-mediated end joining (MMEJ)-inducing single guide RNA/Cas9 protein complex. We showed that effective gene knockdown is maintained in F0 adult fish, enabling recapitulation of both salutary modifying effects of the mtor haploinsufficiency and deleterious modifying effects of the dnajb6b gene on bag3 cardiomyopathy. We finally deployed the F0-based genetic assay to screen differentially expressed genes in the bag3 cardiomyopathy model. As a result, myh9b was identified as a novel modifier gene for bag3 cardiomyopathy. Together, these data prove the feasibility of an F0 adult zebrafish-based genetic assay that can be effectively used to discover modifier genes for inherited cardiomyopathy.
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
Moore, Donald C. , Peery, Matthew R. , Tobon, Katherine, Raheem, Farah , Hwang, Grace, Alhennawi, Lin, Hughes, Mitchell E.

Mayo Clinic

Journal of Oncology Pharmacy Practice | April 26, 2022 | Volume: 28 | Issue: 8 | Pages: 1848-1858

10.1177/10781552221096165 | PMID 35469489 Get It

Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first line chemoimmunotherapy, necessitating second-line salvage therapy. This has historically consisted of platinum-based chemotherapy regimens followed by autologous hematopoietic stem cell transplantation with curative intent for transplant-eligible patients or palliative chemotherapy for transplant-ineligible patients. In recent years there have been several new therapeutic agents approved for the treatment of relapsed/refractory DLBCL, thereby expanding the therapeutic landscape. These agents include polatuzumab vedotin, tafasitamab, loncastuximab tesirine, selinexor, and anti-CD19 chimeric antigen receptor T-cell therapies such as axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. This review summarizes the pharmacology, efficacy, safety, dosing, and administration of new agents recently approved for the treatment of relapsed/refractory DLBCL.